Welcome to LookChem.com Sign In|Join Free
  • or
trans-methanesulfonic acid 4-[4-(N-(tert-butoxycarbonyl)-N-methylamino)cyclohexyl]but-3-ynyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

400899-57-2

Post Buying Request

400899-57-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

400899-57-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 400899-57-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,0,8,9 and 9 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 400899-57:
(8*4)+(7*0)+(6*0)+(5*8)+(4*9)+(3*9)+(2*5)+(1*7)=152
152 % 10 = 2
So 400899-57-2 is a valid CAS Registry Number.

400899-57-2Relevant academic research and scientific papers

Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells

Staedler, Davide,Chapuis-Bernasconi, Catherine,Dehmlow, Henrietta,Fischer, Holger,Juillerat-Jeanneret, Lucienne,Aebi, Johannes D.

supporting information; experimental part, p. 4990 - 5002 (2012/08/28)

Ten oxidosqualene cyclase inhibitors with high efficacy as cholesterol-lowering agents and of different chemical structure classes were evaluated as potential anticancer agents against human cancer cells from various tissue origins and nontumoral human-brain-derived endothelial cells. Inhibition of cancer cell growth was demonstrated at micromolar concentrations, comparable to the concentrations of statins necessary for antitumor effect. Human glioblastoma cells were among the most sensitive cells. These compounds were also able to decrease the proliferation of angiogenic brain-derived endothelial cells, as a model of tumor-induced neovasculation. Additive effects in human glioblastoma cells were also demonstrated for oxidosqualene cyclase inhibitors in combination with atorvastatin while maintaining selectivity against endothelial cells. Thus, not only statins targeting the 3-hydroxy-3- methylglutaryl coenzyme A reductase but also inhibitors of oxidosqualene cyclase decrease tumor growth, suggesting new therapeutic opportunities of combined anti-cholesterol agents for dual treatment of glioblastoma.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 400899-57-2